Neurocognitive trajectory and proteomic signature of inherited risk for Alzheimer's disease

• Published in: PLoS genetics 2022-09, Vol.18 (9), p.e1010294-e1010294
• Main Authors: Paranjpe, Manish D, Chaffin, Mark, Zahid, Sohail, Ritchie, Scott, Rotter, Jerome I, Rich, Stephen S, Gerszten, Robert, Guo, Xiuqing, Heckbert, Susan, Tracy, Russ, Danesh, John, Lander, Eric S, Inouye, Michael, Kathiresan, Sekar, Butterworth, Adam S, Khera, Amit V
• Format: Article
• Language: English
• Subjects: Adult; Age; Aged; Alzheimer Disease - pathology; Alzheimer's disease; Analysis; Apolipoprotein E; Aptamers; Arteriosclerosis; Asymptomatic; Biobanks; Biology and Life Sciences; Biomarkers; Blood donors; Cognition; Cognitive ability; Cross-Sectional Studies; Datasets; Dementia disorders; Genetic aspects; Genome-wide association studies; Genome-Wide Association Study; Genomes; Haplotypes; Humans; Medical diagnosis; Medicine and Health Sciences; Middle Aged; Morbidity; Multifactorial traits; Neurodegenerative diseases; Physical Sciences; Proteomics; Public health; Ratios; Research and Analysis Methods; Risk factors; Statistical analysis
• ISSN: 1553-7404; 1553-7390; 1553-7404
• DOI: 10.1371/journal.pgen.1010294

For Alzheimer's disease-a leading cause of dementia and global morbidity-improved identification of presymptomatic high-risk individuals and identification of new circulating biomarkers are key public health needs. Here, we tested the hypothesis that a polygenic predictor of risk for Alzheimer's disease would identify a subset of the population with increased risk of clinically diagnosed dementia, subclinical neurocognitive dysfunction, and a differing circulating proteomic profile. Using summary association statistics from a recent genome-wide association study, we first developed a polygenic predictor of Alzheimer's disease comprised of 7.1 million common DNA variants. We noted a 7.3-fold (95% CI 4.8 to 11.0; p < 0.001) gradient in risk across deciles of the score among 288,289 middle-aged participants of the UK Biobank study. In cross-sectional analyses stratified by age, minimal differences in risk of Alzheimer's disease and performance on a digit recall test were present according to polygenic score decile at age 50 years, but significant gradients emerged by age 65. Similarly, among 30,541 participants of the Mass General Brigham Biobank, we again noted no significant differences in Alzheimer's disease diagnosis at younger ages across deciles of the score, but for those over 65 years we noted an odds ratio of 2.0 (95% CI 1.3 to 3.2; p = 0.002) in the top versus bottom decile of the polygenic score. To understand the proteomic signature of inherited risk, we performed aptamer-based profiling in 636 blood donors (mean age 43 years) with very high or low polygenic scores. In addition to the well-known apolipoprotein E biomarker, this analysis identified 27 additional proteins, several of which have known roles related to disease pathogenesis. Differences in protein concentrations were consistent even among the youngest subset of blood donors (mean age 33 years). Of these 28 proteins, 7 of the 8 proteins with concentrations available were similarly associated with the polygenic score in participants of the Multi-Ethnic Study of Atherosclerosis. These data highlight the potential for a DNA-based score to identify high-risk individuals during the prolonged presymptomatic phase of Alzheimer's disease and to enable biomarker discovery based on profiling of young individuals in the extremes of the score distribution.